Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 29, 2024 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
February 14, 2024 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus...
February 08, 2024 08:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
January 24, 2024 09:10 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center...
January 22, 2024 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center...
January 10, 2024 18:48 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、膵臓がん治療を目的としたアストラゼネカ (AstraZeneca) のImfinzi® (デュルバルマブ) との併用によるAmpligen® (リンタトリモド) を評価する第Ib/II相試験の登録開始を発表

オランダ、ロッテルダムのエラスムス医療センター (Erasmus Medical Center) で、間もなく最初の登録および最初の被験者への投与を予定経営陣による同発表とその意義についての説明は動画を参照されたい。フロリダ州オカラ発, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE...
January 10, 2024 18:48 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech 宣布开展评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi® (durvalumab) 联合用药治疗胰腺癌疗效的 1b/2 期研究的开放招募

首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行管理层在以下视频中对本公告及其意义进行了讨论，视频链接为：视频奥卡拉，佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国 NYSE：AIM）（简称“AIM”或“公司”）今日宣布，在 Erasmus...
January 10, 2024 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...
November 28, 2023 13:24 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、2つの重要な米国特許を取得し、Ampligen®の知的財産を強化

癌･ME/CFS治療薬Ampligenの米国における独占権を2039年まで延長経営陣が特許の取得とその意味について簡単な動画で説明している。こちらフロリダ州オカラ発 , Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE American: AIM) (「AIM」または「同社」)...
November 28, 2023 13:24 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech 获得两项重要美国专利，增强了 Ampligen® 的知识产权资产实力

Ampligen 治疗癌症和肌痛性脑脊髓炎 (ME)/慢性疲劳综合征 (CFS) 的某些美国独家权利延长至 2039 年管理层在一段简短的视频中讨论了专利的颁发及其意义：点击此处佛罗里达州奥卡拉, Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...